Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Authors

Pencho Genov (ORCID: https://orcid.org/0009-0009-3054-5136)
Nikola V. Mihaylov
Alexandre Khuskivadze (ORCID: https://orcid.org/0000-0002-2308-8792)
Michael J. Louie (ORCID: https://orcid.org/0000-0001-5464-8986)
Vasyl Terzi
William C. Huang (ORCID: https://orcid.org/0000-0001-5261-0650)
Sandip M. Prasad
Dimitar Shishkov
Andrew Meads (ORCID: https://orcid.org/0000-0002-0847-1005)
Mark Schoenberg (ORCID: https://orcid.org/0000-0002-7124-0576)
Sunil Raju
Max Kates (ORCID: https://orcid.org/0000-0003-1166-7225)
Brent Burger

Institutions

Albert Einstein College of Medicine (US)
Montefiore Medical Center (US)
Johns Hopkins University (US)
Morristown Medical Center (US)
Johns Hopkins Bayview Medical Center (US)
NYU Langone Health (US)
National Institute of Emergency Medicine "Pirogov" (BG)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-02-10
DOI: https://doi.org/10.1200/jco.2025.43.5_suppl.776
Primary Topic: Bladder and Urothelial Cancer Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Funders

UroGen Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Pencho Genov, Nikola V. Mihaylov, Alexandre Khuskivadze, Michael J. Louie et al.

Feb 10, 2025

Journal of Clinical Oncology

Bladder and Urothelial Cancer Treatments

article

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Pencho Genov, Nikola V. Mihaylov, Alexandre Khuskivadze, Michael J. Louie, Vasyl Terzi, William C. Huang, Sandip M. Prasad, Dimitar Shishkov, Andrew Meads, Mark Schoenberg, Sunil Raju, Max Kates, Brent Burger

February 10, 2025article en

Abstract

No abstract available for this paper.

Journal of Clinical OncologyVol. 43(5_suppl)

Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Johns Hopkins University (US), Morristown Medical Center (US), Johns Hopkins Bayview Medical Center (US), NYU Langone Health (US), National Institute of Emergency Medicine "Pirogov" (BG)

UroGen Pharma

Openalex Percentile: Top 95%

Bladder and Urothelial Cancer Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial. — Pencho Genov, Nikola V. Mihaylov, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS